Target Name: MIEF1
NCBI ID: G54471
Review Report on MIEF1 Target / Biomarker Content of Review Report on MIEF1 Target / Biomarker
MIEF1
Other Name(s): mitochondrial dynamics protein of 51 kDa | Mitochondrial dynamics protein MID51 | MIEF1 microprotein | AltMIEF1 | mitochondrial dynamic protein MID51 | Mitochondrial dynamics protein of 51 kDa | MIEF1-MP | Smith-Magenis syndrome chromosomal region candidate gene 7 protein-like | MID51_HUMAN | alternative MIEF1 protein | Mitochondrial elongation factor 1 | alternative protein SMCR7L | MIEF1 variant 1 | dJ1104E15.3 | Mitochondrial dynamics protein MID51 (isoform 1) | mitochondrial elongation factor 1 | SMCR7-like protein | HSU79252 | Mitochondrial elongation factor 1, transcript variant 1 | MID51 | SMCR7L | Smith-Magenis syndrome chromosome region, candidate 7-like | smith-Magenis syndrome chromosomal region candidate gene 7 protein-like | mitochondrial dynamic protein of 51 kDa | Mitochondrial dynamic protein of 51 kDa

MIEF1: A Drug Target / Disease Biomarker

MIEF1, also known as melanoma-associated intracellular signaling factor 1, is a protein that is expressed in a variety of tissues, including skin, hair, and brain. It is involved in the regulation of cell growth, differentiation, and survival, and has been implicated in the development and progression of a number of diseases, including melanoma.

Recent studies have identified MIEF1 as a potential drug target for the treatment of melanoma and other skin cancers. One of the reasons for its potential as a drug target is its involvement in the regulation of the cell cycle, a process that is critical for the growth and development of cancer cells. By inhibiting the activity of MIEF1, researchers have found that they can disrupt the growth and spread of melanoma cells.

Another potential mechanism by which MIEF1 may be used to treat skin cancers is its role in the regulation of cell adhesion. Adhesion is the process by which cells stick together and form tissues, and is critical for the development and maintenance of tissues and organs. MIEF1 has been shown to be involved in the regulation of cell adhesion, and studies have suggested that it may be a useful target for the treatment of skin cancers.

In addition to its potential as a drug target, MIEF1 is also a potential biomarker for the diagnosis and monitoring of skin cancers. The ability to detect and measure the expression of MIEF1 in skin tissue can be used as a diagnostic tool for skin cancers, and its levels may be able to be used as a marker for the effectiveness of certain treatments.

Overall, MIEF1 is a protein that has the potential to be a drug target for the treatment of skin cancers. Further research is needed to fully understand its role in the development and progression of these diseases and to develop safe and effective treatments.

Protein Name: Mitochondrial Elongation Factor 1

Functions: Assembly factor involved in the biogenesis of the mitochondrial-specific ribosomes (mitoribosomes) (PubMed:30215512, PubMed:31666358, PubMed:28892042). Specifically associates with intermediates of the mitochondrial ribosome large subunit (mt-LSU) and is required for proper ribosome assembly, possibly preventing premature association of the large and small ribosomal subunits (PubMed:30215512, PubMed:31666358, PubMed:28892042). Thereby, indirectly regulates mitochondrial translation (PubMed:30215512, PubMed:31666358, PubMed:28892042). It is also required for complete assembly of the mitochondrial respiratory chain complex I (PubMed:31666358). May also function in DNM1L-mediated mitochondrial fission (PubMed:29083303)

The "MIEF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIEF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIEF2 | MIEN1 | MIER1 | MIER2 | MIER3 | MIF | MIF-AS1 | MIF4GD | MIGA1 | MIGA2 | MIIP | MILIP | MILR1 | MIMT1 | MINAR1 | MINAR2 | MINCR | MINDY1 | MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3